• / Free eNewsletters & Magazine
  • / My Account
Home>Hayman Capital's Kyle Bass Vows to Continue Drug-Patent Challenges

Hayman Capital's Kyle Bass Vows to Continue Drug-Patent Challenges

3party Content

Fri, 4 Sep 2015

By Joseph Walker Hedge-fund manager Kyle Bass says he'll persist in his campaign to invalidate what he calls weak pharmaceutical patents, despite being handed two early setbacks in recent weeks. "I've spent years of my life working on this and my arguments are as good as can be," Mr. Bass said in
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.